Literature DB >> 2069849

A critical analysis of prognostic factors for survival in intermediate and high grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group Therapy Working Party.

R L Hayward1, R C Leonard, R J Prescott.   

Abstract

Between 1979 and 1987 the Scotland and Newcastle Lymphoma Group registered 972 adults with Working Formulation high or intermediate grade non-Hodgkin's lymphoma. Clinical, pathological and investigational data were recorded prospectively on a computer database allowing analysis for prognostic factors. We have derived prognostically important characteristics and have tested prospectively the validity of the prognostic index on a geographically distinct sub-set of patients from the Edinburgh/Borders clinics. Multivariate analysis showed the following factors to be important in declining order of power; advancing age, worsening performance status, CNS/liver involvement, abnormal white cell count, 'B' symptoms and advancing clinical stage. Patient individual scores allowed them to be aggregated into one of three distinct prognostic groupings separated by arbitrary cut-points into a Best Group (39%) where the median survival exceeds 5 years (53% alive at 5 years), an Intermediate Group (30%) with median survival of 21 months (21% alive at 5 years), and a Worst Group (31%) whose median survival is 7 months (8% alive at 5 years). Similar prognostic group separations occurred when analysis was confined to: patients younger than 70 years; patients treated with initial chemotherapy; patients treated with initial radiotherapy; patients within any of the major pathological sub-groups.

Entities:  

Mesh:

Year:  1991        PMID: 2069849      PMCID: PMC1972546          DOI: 10.1038/bjc.1991.207

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

1.  Malignant lymphomas of follicular center cell origin in man. III. Prognostic features.

Authors:  R S Stein; J Cousar; J M Flexner; S E Graber; L C McKee; S Krantz; R C Collins
Journal:  Cancer       Date:  1979-12       Impact factor: 6.860

2.  Recent trends in the treatment of non-Hodgkin's lymphomas.

Authors:  G Bonadonna; A Lattuada; A Banfi
Journal:  Eur J Cancer       Date:  1976-09       Impact factor: 9.162

Review 3.  Interpretation of clinical trials in diffuse large-cell lymphoma.

Authors:  J O Armitage; B D Cheson
Journal:  J Clin Oncol       Date:  1988-08       Impact factor: 44.544

4.  Potential for prolonged disease-free survival following combination chemotherapy of non-Hodgkin's lymphoma.

Authors:  P S Schein; B A Chabner; G P Canellos; R C Young; C Berard; V T DeVita
Journal:  Blood       Date:  1974-02       Impact factor: 22.113

5.  Advanced diffuse histiocytic lymphoma, a potentially curable disease.

Authors:  V T DeVita; G P Canellos; B Chabner; P Schein; S P Hubbard; R C Young
Journal:  Lancet       Date:  1975-02-01       Impact factor: 79.321

6.  Factors predicting for response and survival in adults with advanced non-Hodgkin's lymphoma.

Authors:  F Cabanillas; J S Burke; T L Smith; T E Moon; J J Butler; V Rodriguez
Journal:  Arch Intern Med       Date:  1978-03

7.  Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy.

Authors:  R I Fisher; V T DeVita; B L Johnson; R Simon; R C Young
Journal:  Am J Med       Date:  1977-08       Impact factor: 4.965

8.  Diffuse large cell and undifferentiated lymphomas with prominent mediastinal involvement.

Authors:  D L Trump; R B Mann
Journal:  Cancer       Date:  1982-07-15       Impact factor: 6.860

9.  Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen.

Authors:  J Laurence; M Coleman; S L Allen; R T Silver; M Pasmantier
Journal:  Ann Intern Med       Date:  1982-08       Impact factor: 25.391

10.  Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP).

Authors:  J O Armitage; F R Dick; M P Corder; S C Garneau; C E Platz; D J Slymen
Journal:  Cancer       Date:  1982-11-01       Impact factor: 6.860

View more
  3 in total

Review 1.  Non-Hodgkin's lymphoma in the elderly: a guide to drug treatment.

Authors:  N Niitsu
Journal:  Drugs Aging       Date:  1999-06       Impact factor: 3.923

2.  Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin's lymphoma in first complete remission. Newcastle and Northern Lymphoma Group.

Authors:  G H Jackson; A L Lennard; P R Taylor; P Carey; B Angus; H Lucraft; R G Evans; S J Proctor
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

3.  Non-Hodgkin's lymphomas in Turkey: eighteen years' experience at the Hacettepe University.

Authors:  I Barista; G Tekuzman; D Firat; E Baltali; E Kansu; A Kars; Y Ozisik; S Ruacan; B Uzunalimoğlu; E Karaağaoğlu
Journal:  Jpn J Cancer Res       Date:  1994-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.